{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:43:30Z","timestamp":1793835810315,"version":"4.6.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["11700"],"award-info":[{"award-number":["11700"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.xcrm.2022.100915","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T12:27:35Z","timestamp":1674044855000},"page":"100915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma"],"prefix":"10.1016","volume":"4","author":[{"given":"Gaurav Kumar","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Landman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Neikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Hulsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"Lieftink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick","family":"Beijersbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Kalyan","family":"Kolluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam M.","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9526-3748","authenticated-orcid":false,"given":"Jitendra","family":"Badhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"van Lohuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2022.100915_bib1","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 Years' experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100915_bib3","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2022.100915_bib4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2022.100915_bib5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1479-5876-10-179","article-title":"BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs","volume":"10","author":"Carbone","year":"2012","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.xcrm.2022.100915_bib6","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.xcrm.2022.100915_bib7","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2022.100915_bib8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2022.100915_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2022.100915_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib11","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrm4067","article-title":"Targeting Polycomb systems to regulate gene expression: modifications to a complex story","volume":"16","author":"Blackledge","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2022.100915_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100915_bib13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer","volume":"6","author":"Sparmann","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2022.100915_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc2736","article-title":"Polycomb group proteins: navigators of lineage pathways led astray in cancer","volume":"9","author":"Bracken","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2022.100915_bib15","doi-asserted-by":"crossref","first-page":"e20191257","DOI":"10.1084\/jem.20191257","article-title":"Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice","volume":"217","author":"Badhai","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2022.100915_bib16","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2022.100915_bib17","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2022.100915_bib18","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers13071591","article-title":"CRISPR screens in synthetic lethality and combinatorial therapies for cancer","volume":"13","author":"Castells-Roca","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2022.100915_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2022.100915_bib20","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xcrm.2022.100915_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2022.100915_bib22","doi-asserted-by":"crossref","first-page":"626971","DOI":"10.3389\/fonc.2021.626971","article-title":"The mevalonate pathway, a metabolic target in cancer therapy","volume":"11","author":"Guerra","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.celrep.2016.05.096","article-title":"NeuCode proteomics reveals Bap1 regulation of metabolism","volume":"16","author":"Baughman","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2022.100915_bib24","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s13063-018-2851-9","article-title":"Zoledronic acid in the management of mesothelioma - a feasibility study (Zol-A Trial): study protocol for a randomised controlled trial","volume":"19","author":"de Fonseka","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.xcrm.2022.100915_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/TCRM.S2707","article-title":"Zoledronic acid in the management of metastatic bone disease","volume":"4","author":"Polascik","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.xcrm.2022.100915_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2165\/0002512-200825110-00007","article-title":"Zoledronic acid: a review of its use in the treatment of osteoporosis","volume":"25","author":"Deeks","year":"2008","journal-title":"Drugs Aging"},{"key":"10.1016\/j.xcrm.2022.100915_bib27","first-page":"39","article-title":"A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma","volume":"8","author":"Jamil","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.xcrm.2022.100915_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.aav4902","article-title":"Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1","volume":"364","author":"He","year":"2019","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.xcrm.2022.100915_bib29","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1016\/j.molcel.2021.06.020","article-title":"BAP1 enhances Polycomb repression by counteracting widespread H2AK119ub1 deposition and chromatin condensation","volume":"81","author":"Conway","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2022.100915_bib30","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1038\/s41467-021-25529-z","article-title":"Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression","volume":"12","author":"Bakhoum","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2022.100915_bib31","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41422-018-0079-6","article-title":"Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR\/PI3K\/AKT drives breast carcinogenesis","volume":"28","author":"He","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.xcrm.2022.100915_bib32","series-title":"Vatalanib in Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia Group B (CALGB 30107)","first-page":"393","volume":"76","author":"Jahan","year":"2012"},{"key":"10.1016\/j.xcrm.2022.100915_bib33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2020.00126","article-title":"Antiangiogeneic strategies in mesothelioma","volume":"10","author":"Nowak","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41419-021-03760-2","article-title":"Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2022.100915_bib36","doi-asserted-by":"crossref","first-page":"6661534","DOI":"10.1155\/2021\/6661534","article-title":"Zoledronic acid enhanced the antitumor effect of cisplatin on orthotopic osteosarcoma by ROS-PI3K\/AKT signaling and attenuated osteolysis","volume":"2021","author":"Liu","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.xcrm.2022.100915_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","article-title":"Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in\u00a0vivo and in MCF-7 cells in\u00a0vitro","volume":"157","author":"R\u00e4ikk\u00f6nen","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.xcrm.2022.100915_bib38","doi-asserted-by":"crossref","first-page":"e72430","DOI":"10.7554\/eLife.72430","article-title":"Bisphosphonate drugs have actions in the lung and inhibit the mevalonate pathway in alveolar macrophages","volume":"10","author":"Munoz","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2022.100915_bib39","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jbmr.4030","article-title":"Nitrogen-containing bisphosphonates are associated with reduced risk of pneumonia in patients with hip fracture","volume":"35","author":"Sing","year":"2020","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.xcrm.2022.100915_bib40","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100915_bib41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2022.100915_bib42","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1200\/JCO.2015.63.2471","article-title":"Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer","volume":"33","author":"Corcoran","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2022.100915_bib44","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib45","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.molonc.2014.05.004","article-title":"Drug resistance to targeted therapies: deja vu all over again","volume":"8","author":"Groenendijk","year":"2014","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2022.100915_bib46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100915_bib47","series-title":"A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma","first-page":"87","volume":"140","author":"Lam","year":"2020"},{"key":"10.1016\/j.xcrm.2022.100915_bib56","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.xcrm.2022.100915_bib57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.2951","article-title":"Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing","volume":"32","author":"Heckl","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.xcrm.2022.100915_bib53","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2022.100915_bib55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome biology"},{"key":"10.1016\/j.xcrm.2022.100915_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2022.100915_bib49","doi-asserted-by":"crossref","first-page":"18507","DOI":"10.1073\/pnas.0806213105","article-title":"Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats","volume":"105","author":"Herold","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2022.100915_bib50","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature08398","article-title":"Role of the polycomb protein EED in the propagation of repressive histone marks","volume":"461","author":"Margueron","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2022.100915_bib51","doi-asserted-by":"crossref","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","article-title":"ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays","volume":"9","author":"Guzm\u00e1n","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2022.100915_bib52","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.1038\/s41598-019-45839-z","article-title":"The ENCODE blacklist: identification of problematic regions of the genome","volume":"9","author":"Amemiya","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2022.100915_bib54","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122004943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379122004943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:14:35Z","timestamp":1778919275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379122004943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2666379122004943"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100915","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2022.100915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"100915"}}